Cargando…
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study
Lasmiditan is a centrally penetrant, highly selective 5‐hydroxytryptamine (serotonin) receptor 1F (5HT(1F)) agonist under development as a novel therapy for acute treatment of migraine. A phase 1 randomized, placebo‐ and positive‐controlled crossover study assessed the abuse potential of lasmiditan...
Autores principales: | Wilbraham, Darren, Berg, Paul H., Tsai, Max, Liffick, Emily, Loo, Li Shen, Doty, Erin Gautier, Sellers, Edward |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078915/ https://www.ncbi.nlm.nih.gov/pubmed/31745991 http://dx.doi.org/10.1002/jcph.1543 |
Ejemplares similares
-
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls
por: Pearlman, Eric M., et al.
Publicado: (2020) -
Analgesic effect of oral ibuprofen 400, 600, and 800 mg; paracetamol 500 and 1000 mg; and paracetamol 1000 mg plus 60 mg codeine in acute postoperative pain: a single-dose, randomized, placebo-controlled, and double-blind study
por: Lyngstad, Gaute, et al.
Publicado: (2021) -
Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019) -
Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction
por: Schalekamp, Tom, et al.
Publicado: (2007) -
The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia
por: Krysiak, Robert, et al.
Publicado: (2011)